Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
264.1 USD | -0.59% | -0.89% | -8.32% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.32% | 142B | |
+28.79% | 676B | |
+24.87% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+3.02% | 210B | |
-0.25% | 204B | |
-9.86% | 194B | |
-11.71% | 144B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- US Antitrust Regulator Says It's Suing to Block Amgen's Acquisition of Horizon Therapeutics